Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats

Bethany P. Cummings, Ahmed Bettaieb, James L. Graham, Kimber Stanhope, Fawaz Haj, Peter J Havel

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There is a need to identify strategies for type 2 diabetes prevention. Therefore, we investigated the efficacy of pioglitazone and alogliptin alone and in combination to prevent type 2 diabetes onset in UCD-T2DM rats, a model of polygenic obese type 2 diabetes. At 2 months of age, rats were divided into four groups: control, alogliptin (20 mg/kg per day), pioglitazone (2.5 mg/kg per day), and alogliptinCpioglitazone. Non-fasting blood glucose was measured weekly to determine diabetes onset. Pioglitazone alone and in combination with alogliptin lead to a 5-month delay in diabetes onset despite promoting increased food intake and body weight (BW). Alogliptin alone did not delay diabetes onset or affect food intake or BW relative to controls. Fasting plasma glucose, insulin, and lipid concentrations were lower and adiponectin concentrations were threefold higher in groups treated with pioglitazone. All treatment groups demonstrated improvements in glucose tolerance and insulin secretion during an oral glucose tolerance test with an additive improvement observed with alogliptinCpioglitazone. Islet histology revealed an improvement of islet morphology in all treatment groups compared with control. Pioglitazone treatment also resulted in increased expression of markers of mitochondrial biogenesis in brown adipose tissue and white adipose tissue, with mild elevations observed in animals treated with alogliptin alone. Pioglitazone markedly delays the onset of type 2 diabetes in UCD-T2DM rats through improvements of glucose tolerance, insulin sensitivity, islet function, and markers of adipose mitochondrial biogenesis; however, addition of alogliptin at a dose of 20 mg/kg per day to pioglitazone treatment does not enhance the prevention/delay of diabetes onset.

Original languageEnglish (US)
Pages (from-to)133-144
Number of pages12
JournalJournal of Endocrinology
Volume221
Issue number1
DOIs
StatePublished - Apr 2014

Fingerprint

pioglitazone
Type 2 Diabetes Mellitus
Organelle Biogenesis
Glucose
Eating
Body Weight
Insulin
White Adipose Tissue
Brown Adipose Tissue
Adiponectin
Therapeutics
Glucose Tolerance Test
alogliptin
Insulin Resistance
Blood Glucose
Fasting
Histology

Keywords

  • Alogliptin
  • Islet
  • Pioglitazone
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. / Cummings, Bethany P.; Bettaieb, Ahmed; Graham, James L.; Stanhope, Kimber; Haj, Fawaz; Havel, Peter J.

In: Journal of Endocrinology, Vol. 221, No. 1, 04.2014, p. 133-144.

Research output: Contribution to journalArticle

Cummings, Bethany P. ; Bettaieb, Ahmed ; Graham, James L. ; Stanhope, Kimber ; Haj, Fawaz ; Havel, Peter J. / Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. In: Journal of Endocrinology. 2014 ; Vol. 221, No. 1. pp. 133-144.
@article{a6f840bca2eb4e429fb7196f15b69bb2,
title = "Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats",
abstract = "There is a need to identify strategies for type 2 diabetes prevention. Therefore, we investigated the efficacy of pioglitazone and alogliptin alone and in combination to prevent type 2 diabetes onset in UCD-T2DM rats, a model of polygenic obese type 2 diabetes. At 2 months of age, rats were divided into four groups: control, alogliptin (20 mg/kg per day), pioglitazone (2.5 mg/kg per day), and alogliptinCpioglitazone. Non-fasting blood glucose was measured weekly to determine diabetes onset. Pioglitazone alone and in combination with alogliptin lead to a 5-month delay in diabetes onset despite promoting increased food intake and body weight (BW). Alogliptin alone did not delay diabetes onset or affect food intake or BW relative to controls. Fasting plasma glucose, insulin, and lipid concentrations were lower and adiponectin concentrations were threefold higher in groups treated with pioglitazone. All treatment groups demonstrated improvements in glucose tolerance and insulin secretion during an oral glucose tolerance test with an additive improvement observed with alogliptinCpioglitazone. Islet histology revealed an improvement of islet morphology in all treatment groups compared with control. Pioglitazone treatment also resulted in increased expression of markers of mitochondrial biogenesis in brown adipose tissue and white adipose tissue, with mild elevations observed in animals treated with alogliptin alone. Pioglitazone markedly delays the onset of type 2 diabetes in UCD-T2DM rats through improvements of glucose tolerance, insulin sensitivity, islet function, and markers of adipose mitochondrial biogenesis; however, addition of alogliptin at a dose of 20 mg/kg per day to pioglitazone treatment does not enhance the prevention/delay of diabetes onset.",
keywords = "Alogliptin, Islet, Pioglitazone, Type 2 diabetes",
author = "Cummings, {Bethany P.} and Ahmed Bettaieb and Graham, {James L.} and Kimber Stanhope and Fawaz Haj and Havel, {Peter J}",
year = "2014",
month = "4",
doi = "10.1530/JOE-13-0601",
language = "English (US)",
volume = "221",
pages = "133--144",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "1",

}

TY - JOUR

T1 - Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats

AU - Cummings, Bethany P.

AU - Bettaieb, Ahmed

AU - Graham, James L.

AU - Stanhope, Kimber

AU - Haj, Fawaz

AU - Havel, Peter J

PY - 2014/4

Y1 - 2014/4

N2 - There is a need to identify strategies for type 2 diabetes prevention. Therefore, we investigated the efficacy of pioglitazone and alogliptin alone and in combination to prevent type 2 diabetes onset in UCD-T2DM rats, a model of polygenic obese type 2 diabetes. At 2 months of age, rats were divided into four groups: control, alogliptin (20 mg/kg per day), pioglitazone (2.5 mg/kg per day), and alogliptinCpioglitazone. Non-fasting blood glucose was measured weekly to determine diabetes onset. Pioglitazone alone and in combination with alogliptin lead to a 5-month delay in diabetes onset despite promoting increased food intake and body weight (BW). Alogliptin alone did not delay diabetes onset or affect food intake or BW relative to controls. Fasting plasma glucose, insulin, and lipid concentrations were lower and adiponectin concentrations were threefold higher in groups treated with pioglitazone. All treatment groups demonstrated improvements in glucose tolerance and insulin secretion during an oral glucose tolerance test with an additive improvement observed with alogliptinCpioglitazone. Islet histology revealed an improvement of islet morphology in all treatment groups compared with control. Pioglitazone treatment also resulted in increased expression of markers of mitochondrial biogenesis in brown adipose tissue and white adipose tissue, with mild elevations observed in animals treated with alogliptin alone. Pioglitazone markedly delays the onset of type 2 diabetes in UCD-T2DM rats through improvements of glucose tolerance, insulin sensitivity, islet function, and markers of adipose mitochondrial biogenesis; however, addition of alogliptin at a dose of 20 mg/kg per day to pioglitazone treatment does not enhance the prevention/delay of diabetes onset.

AB - There is a need to identify strategies for type 2 diabetes prevention. Therefore, we investigated the efficacy of pioglitazone and alogliptin alone and in combination to prevent type 2 diabetes onset in UCD-T2DM rats, a model of polygenic obese type 2 diabetes. At 2 months of age, rats were divided into four groups: control, alogliptin (20 mg/kg per day), pioglitazone (2.5 mg/kg per day), and alogliptinCpioglitazone. Non-fasting blood glucose was measured weekly to determine diabetes onset. Pioglitazone alone and in combination with alogliptin lead to a 5-month delay in diabetes onset despite promoting increased food intake and body weight (BW). Alogliptin alone did not delay diabetes onset or affect food intake or BW relative to controls. Fasting plasma glucose, insulin, and lipid concentrations were lower and adiponectin concentrations were threefold higher in groups treated with pioglitazone. All treatment groups demonstrated improvements in glucose tolerance and insulin secretion during an oral glucose tolerance test with an additive improvement observed with alogliptinCpioglitazone. Islet histology revealed an improvement of islet morphology in all treatment groups compared with control. Pioglitazone treatment also resulted in increased expression of markers of mitochondrial biogenesis in brown adipose tissue and white adipose tissue, with mild elevations observed in animals treated with alogliptin alone. Pioglitazone markedly delays the onset of type 2 diabetes in UCD-T2DM rats through improvements of glucose tolerance, insulin sensitivity, islet function, and markers of adipose mitochondrial biogenesis; however, addition of alogliptin at a dose of 20 mg/kg per day to pioglitazone treatment does not enhance the prevention/delay of diabetes onset.

KW - Alogliptin

KW - Islet

KW - Pioglitazone

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84897891308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897891308&partnerID=8YFLogxK

U2 - 10.1530/JOE-13-0601

DO - 10.1530/JOE-13-0601

M3 - Article

C2 - 24627447

AN - SCOPUS:84897891308

VL - 221

SP - 133

EP - 144

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 1

ER -